Mesoblast’s COVID-19 Respiratory Therapy Hits Another Snag on Route to Potential EUA

Shares in  Mesoblast dropped on the last day of August 2021 after the Melbourne-based biotech was told that its investigational respiratory treatment for COVID-19 needs to undergo another trial in order to receive emergency use authorization (EUA) from U.S. Food and Drug Administration (FDA).